These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1909977)

  • 1. Early pituitary desensitization and ovarian suppression with leuprolide acetate is associated with in vitro fertilization-embryo transfer success.
    Seifer DB; Thornton KL; DeCherney AH; Lavy G
    Fertil Steril; 1991 Sep; 56(3):500-4. PubMed ID: 1909977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
    Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
    Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval.
    Meldrum DR; Wisot A; Hamilton F; Gutlay AL; Kempton WF; Huynh D
    Fertil Steril; 1989 Mar; 51(3):455-9. PubMed ID: 2493403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum and follicular fluid (FF) estradiol (E2) levels in ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT) conception cycles after pituitary suppression.
    Leya J; Molo MW; Olson D; Radwanska E
    J In Vitro Fert Embryo Transf; 1991 Jun; 8(3):137-40. PubMed ID: 1919258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian suppression with leuprolide acetate: comparison of luteal, follicular, and flare-up administration in controlled ovarian hyperstimulation for oocyte retrieval.
    Gindoff PR; Hall JL; Stillman RJ
    J In Vitro Fert Embryo Transf; 1990 Apr; 7(2):94-7. PubMed ID: 2113562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study.
    Younis JS; Simon A; Koren R; Dorembus D; Schenker JG; Laufer N
    Fertil Steril; 1992 Sep; 58(3):575-80. PubMed ID: 1387849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of an abnormal response during pituitary desensitization in an in vitro fertilization and embryo transfer program.
    Goswami SK; Chakravarty BN; Kabir SN
    J Assist Reprod Genet; 1996 May; 13(5):374-80. PubMed ID: 8739051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization.
    Tsai HD; Chen CM; Lo HY; Chang CC
    Hum Reprod; 1995 Nov; 10(11):2909-12. PubMed ID: 8747042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of using ganirelix acetate versus a 4-day follicular phase leuprolide acetate protocol in unselected women undergoing in vitro fertilization.
    Posada MN; Vlahos NP; Jurema MW; Bracero NJ; Wallach EE; Garcia JE
    Fertil Steril; 2003 Jul; 80(1):103-10. PubMed ID: 12849810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum progesterone levels predict success of in vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins.
    Silverberg KM; Burns WN; Olive DL; Riehl RM; Schenken RS
    J Clin Endocrinol Metab; 1991 Oct; 73(4):797-803. PubMed ID: 1909704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized study of the optimum timing of human chorionic gonadotropin administration after pituitary desensitization in in vitro fertilization.
    Tan SL; Balen A; el Hussein E; Mills C; Campbell S; Yovich J; Jacobs HS
    Fertil Steril; 1992 Jun; 57(6):1259-64. PubMed ID: 1601148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome?
    Senöz S; Gülekli B; Turhan NO; Ozakşit G; Odabaşi AR; Oral H; Ozcan U; Gökmen O
    Gynecol Endocrinol; 1995 Jun; 9(2):91-6. PubMed ID: 7502695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Very high serum estradiol levels are not detrimental to clinical outcome of in vitro fertilization.
    Chenette PE; Sauer MV; Paulson RJ
    Fertil Steril; 1990 Nov; 54(5):858-63. PubMed ID: 2121555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary down-regulation using leuprolide for the intensive ovulation management of poor prognosis patients having in vitro fertilization (IVF)-related treatments.
    Cummins JM; Yovich JM; Edirisinghe WR; Yovich JL
    J In Vitro Fert Embryo Transf; 1989 Dec; 6(6):345-52. PubMed ID: 2517507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between nafarelin and leuprolide acetate for in vitro fertilization: preliminary clinical study.
    Dantas ZN; Vicino M; Balmaceda JP; Asch RH; Stone SC
    Fertil Steril; 1994 Apr; 61(4):705-8. PubMed ID: 8150114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian stimulation for in vitro fertilization using pure follicle-stimulating hormone with and without gonadotropin-releasing hormone agonist in high-responder patients.
    Edelstein MC; Brzyski RG; Jones GS; Oehninger S; Sieg SM; Muasher SJ
    J In Vitro Fert Embryo Transf; 1990 Jun; 7(3):172-6. PubMed ID: 2116488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of a single half-dose, long-acting form of gonadotropin-releasing hormone analog (GnRH-a) and a short-acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program.
    Hsieh Y; Tsai H; Chang C; Lo H
    Fertil Steril; 2000 Apr; 73(4):817-20. PubMed ID: 10731546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.